Insider Selling: uniQure (NASDAQ:QURE) Insider Sells $1,392,600.00 in Stock

uniQure N.V. (NASDAQ:QURE) insider Walid Abi-Saab sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total value of $1,392,600.00. Following the sale, the insider directly owned 148,235 shares in the company, valued at approximately $6,881,068.70. This represents a 16.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Walid Abi-Saab also recently made the following trade(s):

• On Friday, June 26th, Walid Abi-Saab sold 1,434 shares of uniQure stock. The stock was sold at an average price of $46.86, for a total value of $67,197.24.
• On Friday, May 8th, Walid Abi-Saab sold 45,000 shares of uniQure stock. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00.

uniQure Stock Performance

uniQure stock opened at $41.81 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The company has a fifty day moving average price of $30.53 and a two-hundred day moving average price of $23.86. The company has a market cap of $2.64 billion, a PE ratio of -12.01 and a beta of 0.90.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. Research analysts expect that uniQure N.V. will post -3.63 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. raised its stake in shares of uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock valued at $243,000 after purchasing an additional 533 shares in the last quarter. Arizona State Retirement System grew its position in uniQure by 6.0% in the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after buying an additional 627 shares in the last quarter. Ensign Peak Advisors Inc increased its stake in uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after buying an additional 650 shares during the period. FNY Investment Advisers LLC increased its stake in uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares during the period. Finally, CIBC Private Wealth Group LLC acquired a new position in uniQure during the 3rd quarter valued at about $50,000. 78.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Chardan Capital increased their price objective on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price for the company in a report on Wednesday, June 17th. Leerink Partners increased their price target on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, Barclays raised uniQure from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $25.00 to $65.00 in a report on Thursday, June 18th. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $64.17.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.